Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double-blind, placebo-controlled proof-of concept study of the efficacy and safety of gevokizumab in the treatment of patients with giant cell arteritis

Next Previous
Trial Profile

A randomised, double-blind, placebo-controlled proof-of concept study of the efficacy and safety of gevokizumab in the treatment of patients with giant cell arteritis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gevokizumab (Primary)
  • Indications Giant cell arteritis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors IRIS; Servier

Most Recent Events

  • 19 Nov 2015 There is discrepancy in status among different countries as per EudraCT record (completed, recruiting and discontinued). Kept it as completed as maximum countries are showing the same though global end date is not provided.
  • 14 Nov 2015 Status changed from recruiting to completed as per European Clinical Trials Database record.
  • 10 Apr 2014 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top